Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.ajp.162.11.2191-a | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Potential of Intravenous Ketamine in Early-Onset Dementia: A Case Report.
Cureus
July 2024
Pain Management, Florida Spine Institute, Clearwater, USA.
This case report discusses the use of intravenous (IV) ketamine as a potential therapeutic agent for early-onset dementia. A 56-year-old female with a diagnosis of early-onset dementia showed significant cognitive decline despite trying and failing several standard treatments such as memantine, donepezil, and rivastigmine. Given the promising results of ketamine in other neurological and psychiatric disorders, the patient underwent a series of IV ketamine infusions over a period of two months.
View Article and Find Full Text PDFPediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges.
Paediatr Drugs
July 2024
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd, Suite 4-400, Houston, TX, 77030, USA.
Article Synopsis
- Pediatric OCD is a serious mental health condition that can be hard to treat, and about 10% of kids don't get better with standard treatments.
- Researchers looked at different ways to help those kids who don't respond to normal treatments, including learning from studies done on adults.
- The most promising options for treating these kids include special intensive programs and using certain medications alongside antidepressants, but more research is needed to find the best solutions.
Augmentation Strategies for Partial or Non-responders to Clozapine in Patients with Schizophrenia: A Bayesian Network Meta-analysis of Randomized Controlled Trials.
Clin Psychopharmacol Neurosci
May 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Clozapine is the only approved drug for treatment-resistant schizophrenia, but the response to the drug is often inadequate. Augmentation with other antipsychotics, anticonvulsants, and antidepressants is recommended for such patients, but there is a lack of evidence regarding the most effective therapy. This network meta-analysis was conducted to evaluate the efficacy of pharmacological agents used in the augmentation strategies in patients who were partial/ non-responders to clozapine.
View Article and Find Full Text PDFClinical Indications of Memantine in Psychiatry-Science or Art?
Psychopharmacol Bull
February 2023
Naguy, MBBch, MSc, Child/Adolescent Psychiatrist, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St, Shuwaikh, State of Kuwait.
Background: Memenatine is USFDA approved for dementia of Alzheimer's disease. Apart from this indication, trend of its use in psychiatry is on the rise addressing a multitude of disorders.
Study Question: Memantine remains one of only few psychotropic drugs with antiglutamate activity.
The NMDA receptor antagonists memantine and ketamine as anti-migraine agents.
Naunyn Schmiedebergs Arch Pharmacol
July 2023
Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Migraine is a debilitating disorder affecting females more frequently than males. There is some evidence that drugs targeting glutamate receptors: memantine and ketamine might be beneficial in the therapy of this entity. Therefore, the purpose of this work is to present NMDA receptor antagonists, memantine and ketamine, as potential anti-migraine agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!